Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Ader F. (Author) Other; Bouscambert-Duchamp M. (Author) Other; Hites M. (Author) Other; Peiffer-Smadja N. (Author) Other; Poissy J. (Author) Other; Belhadi D. (Author) Other; Diallo A. (Author) Other; Lê M.P. (Author) Other; Peytavin G. (Author) Other; Staub T. (Author) Other; Greil R. (Author) Other; Guedj J. (Author) Other; Paiva, J-A (Author) FMUP; Costagliola D. (Author) Other; Yazdanpanah Y. (Author) Other; Burdet C. (Author) Other; Mentré F. (Author) Other; Egle A. (Author) Other; Joannidis M. (Author) Other; Lamprecht B. (Author) Other; Altdorfer A. (Author) Other; Belkhir L. (Author) Other; Fraipont V. (Author) Other; Verschelden G. (Author) Other; Aboab J. (Author) Other; Ait-Oufella H. (Author) Other; Andrejak C. (Author) Other; Andreu P. (Author) Other; Argaud L. (Author) Other; Bani-Sadr F. (Author) Other; Benezit F. (Author) Other; Blot M. (Author) Other; Botelho-Nevers E. (Author) Other; Bouadma L. (Author) Other; Bouchaud O. (Author) Other; Bougon D. (Author) Other; Bouiller K. (Author) Other; Bounes-Vardon F. (Author) Other; Boutoille D. (Author) Other; Boyer A. (Author) Other; Bruel C. (Author) Other; Cabié A. (Author) Other; Canet E. (Author) Other; Cazanave C. (Author) Other; Chabartier C. (Author) Other; Chirouze C. (Author) Other; Clere-Jehl R. (Author) Other; Courjon J. (Author) Other; Crockett F. (Author) Other; Danion F. (Author) Other; Delbove A. (Author) Other; Dellamonica J. (Author) Other; Djossou F. (Author) Other; Dubost C. (Author) Other; Duvignaud A. (Author) Other; Epaulard O. (Author) Other; Epelboin L. (Author) Other; Fartoukh M. (Author) Other; Faure K. (Author) Other; Faure E. (Author) Other; Ferry T. (Author) Other; Ficko C. (Author) Other; Figueiredo S. (Author) Other; Gaborit B. (Author) Other; Gaci R. (Author) Other; Gagneux-Brunon A. (Author) Other; Gallien S. (Author) Other; Garot D. (Author) Other; Geri G. (Author) Other; Gibot S. (Author) Other; Goehringer F. (Author) Other; Gousseff M. (Author) Other; Gruson D. (Author) Other; Hansmann Y. (Author) Other; Hinschberger O. (Author) Other; Jaureguiberry S. (Author) Other; Jeanmichel V. (Author) Other; Kerneis S. (Author) Other; Kimmoun A. (Author) Other; Klouche K. (Author) Other; Lachâtre M. (Author) Other; Lacombe K. (Author) Other; Laine F. (Author) Other; Lanoix J.P. (Author) Other; Launay O. (Author) Other; Laviolle B. (Author) Other; Le Moing V. (Author) Other; Le Pavec J. (Author) Other; Le Tulzo Y. (Author) Other; Le Turnier P. (Author) Other; Lebeaux D. (Author) Other; Lefevre B. (Author) Other; Leroy S. (Author) Other; Lescure F.X. (Author) Other; Lessire H. (Author) Other; Leveau B. (Author) Other; Loubet P. (Author) Other; Makinson A. (Author) Other; Malvy D. (Author) Other; Marquette C.H. (Author) Other

Journal

Title: The Lancet Infectious Diseases

Vol. 22

Pages: 209-221

ISSN: 1473-3099

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 189 Citations

Scopus - 198 Citations

Other information

Authenticus ID: P-00W-1V5

DOI: 10.1016/s1473-3099(21)00485-0

Abstract (EN): Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital with COVID-19, with indication of oxygen or ventilator support. Methods DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg). Adult patients (aged >= 18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and illness of any duration were eligible if they had clinical evidence of hypoxaemic pneumonia, or required oxygen supplementation. Exclusion criteria included elevated liver enzymes, severe chronic kidney disease, any contraindication to one of the studied treatments or their use in the 29 days before random assignment, or use of ribavirin, as well as pregnancy or breastfeeding. Participants were randomly assigned (1:1:1:1:1) to receive standard of care alone or in combination with remdesivir, lopinavir-ritonavir, lopinavir-ritonavir and interferon beta-1a, or hydroxychloroquine. Randomisation used computer-generated blocks of various sizes; it was stratified on severity of disease at inclusion and on European administrative region. Remdesivir was administered as 200 mg intravenous infusion on day 1, followed by once daily, 1-h infusions of 100 mg up to 9 days, for a total duration of 10 days. It could be stopped after 5 days if the participant was discharged. The primary outcome was the clinical status at day 15 measured by the WHO seven-point ordinal scale, assessed in the intentionto-treat population. Safety was assessed in the modified intention-to-treat population and was one of the secondary outcomes. This trial is registered with the European Clinical Trials Database, EudraCT2020-000936-23, and ClinicalTrials.gov, NCT04315948. Findings Between March 22, 2020, and Jan 21, 2021, 857 participants were enrolled and randomly assigned to remdesivir plus standard of care (n=429) or standard of care only (n=428). 15 participants were excluded from analysis in the remdesivir group, and ten in the control group. At day 15, the distribution of the WHO ordinal scale was: (1) not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]). The difference between treatment groups was not significant (odds ratio 0.98 [95% CI 0.77-1.25]; p=0.85). There was no significant difference in the occurrence of serious adverse events between treatment groups (remdesivir, 135 [33%] of 406 vs control, 130 [31%] of 418; p=0.48). Three deaths (acute respiratory distress syndrome, bacterial infection, and hepatorenal syndrome) were considered related to remdesivir by the investigators, but only one by the sponsor's safety team (hepatorenal syndrome). Interpretation No clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support. Copyright

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13